Skip to main content

and
  1. No Access

    Article

    A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer

    Patients with locally advanced pancreatic cancer typically have poor outcomes, with a median survival of approximately 16 months. Novel methods to improve outcomes are needed. Nab-paclitaxel (Abraxane) has sho...

    Jacob E. Shabason, Jerry Chen in Cancer Chemotherapy and Pharmacology (2018)

  2. No Access

    Article

    Pelvic Angiosarcoma Occurring in a Postmenopausal Female: Case Report and Review of the Literature

    Jorge Villaran, Arturo Loaiza-Bonilla, Carlos Parra-Herran in Pathology & Oncology Research (2013)

  3. Article

    Open Access

    A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

    5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is superior to gemcitabine in patients with metastatic pancreatic cancer who have a good performance status. We investigated this combination...

    Peter J Hosein, Jessica Macintyre, Carolina Kawamura in BMC Cancer (2012)

  4. Article

    Open Access

    Persistent Tn polyagglutination syndrome during febrile neutropenia: a case report and review of the literature

    Tn polyagglutination syndrome is a rare disorder that has been reported on only a few occasions in the literature, and, to the best of our knowledge, never before in the context of febrile neutropenia.

    Arturo Loaiza-Bonilla, Daniel Horowitz, Sheenu Sheela in Journal of Medical Case Reports (2011)